Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types

Vaccine

Volumn 28, Issue 19, 2010, Pages 3479-3487

  Zhang, Ting ^a   Xu, Yufei ^a   Qiao, Liang ^b   Wang, Youchun ^c   Wu, Xueling ^c   Fan, Dongsheng ^a   Peng, Qinglin ^a   Xu, Xuemei ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

Author keywords

Immune interference; Papillomavirus; Virus like particle

Indexed keywords

ALUMINUM HYDROXIDE; MONOVALENT VACCINE; NEUTRALIZING ANTIBODY; TRIPLE VACCINE; TRIVALENT HUMAN PAPILLOMA VIRUS VACCINE; UNCLASSIFIED DRUG; VACCINE; WART VIRUS VACCINE;

ADJUVANT THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CONTROLLED STUDY; DRUG FORMULATION; DRUG MEGADOSE; HUMORAL IMMUNITY; IN VITRO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VACCINATION; VIRUS LIKE AGENT; VIRUS STRAIN; WART VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BACULOVIRIDAE; CAPSID PROTEINS; DNA, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENETIC VECTORS; IMMUNOLOGIC MEMORY; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; SEQUENCE ANALYSIS, DNA; TIME FACTORS; VACCINES, VIROSOME;

EID: 77950478700     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.02.057     Document Type: Article

References (56)

1. Zur H.H. Papillomaviruses in the causation of human cancers-a brief historical account. Virology 384 February (2) (2009) 260-265
2. Bao Y.P., Li N., Smith J.S., and Qiao Y.L. Human papillomavirus type distribution in women from Asia: a meta-analysis. Int J Gynecol Cancer 18 January (1) (2008) 71-79
3. Bao Y.P., Li N., Smith J.S., and Qiao Y.L. Human papillomavirus type-distribution in the cervix of Chinese women: a meta-analysis. Int J STD AIDS 19 February (2) (2008) 106-111
4. HPV and cervical cancer in the 2007 report. Vaccine 25 November (Suppl. 3) (2007) C1-C230
5. Hagensee M.E., Yaegashi N., and Galloway D.A. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 67 January (1) (1993) 315-322
6. Kirnbauer R., Booy F., Cheng N., Lowy D.R., and Schiller J.T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci USA 89 December (24) (1992) 12180-12184
7. Fleury M.J., Touze A., Alvarez E., Carpentier G., Clavel C., Vautherot J.F., et al. Identification of type-specific and cross-reactive neutralizing conformational epitopes on the major capsid protein of human papillomavirus type 31. Arch Virol 151 August (8) (2006) 1511-1523
8. Marais D., Rose R.C., Lane C., Aspinall S., Bos P., and Williamson A.L. Seroresponses to virus-like particles of human papillomavirus types 16, 18, 31, 33, and 45 in San people of Southern Africa. J Med Virol 60 March (3) (2000) 331-336
9. Marais D.J., Rose R.C., Lane C., Orozco O., and Coursaget P. Seroresponses to human papillomavirus types 16, 18, 31, 33, and 45 virus-like particles in South African women with cervical cancer and cervical intraepithelial neoplasia. J Med Virol 60 April (4) (2000) 403-410
10. Christensen N.D., Kreider J.W., Cladel N.M., Patrick S.D., and Welsh P.A. Monoclonal antibody-mediated neutralization of infectious human papillomavirus type 11. J Virol 64 November (11) (1990) 5678-5681
11. Combita A.L., Bravo M.M., Touze A., Orozco O., and Coursaget P. Serologic response to human oncogenic papillomavirus types 16, 18, 31, 33, 39, 58 and 59 virus-like particles in colombian women with invasive cervical cancer. Int J Cancer 97 February (6) (2002) 796-803
12. Combita A.L., Touze A., Bousarghin L., Christensen N.D., and Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 76 July (13) (2002) 6480-6486
13. Wideroff L., Schiffman M., Haderer P., Armstrong A., Greer C.E., Manos M.M., et al. Seroreactivity to human papillomavirus types 16, 18, 31, and 45 virus-like particles in a case-control study of cervical squamous intraepithelial lesions. J Infect Dis 180 November (5) (1999) 1424-1428
14. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69 June (6) (1995) 3959-3963
15. Jansen K.U., Rosolowsky M., Schultz L.D., Markus H.Z., Cook J.C., Donnelly J.J., et al. Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 13 November (16) (1995) 1509-1514
16. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92 December (25) (1995) 11553-11557
17. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 April (9518) (2006) 1247-1255
18. Jenkins D. A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention. Gynecol Oncol 110 September (3 Suppl. 1) (2008) S18-S25
19. Moscicki A.B. HPV vaccines: today and in the future. J Adolesc Health 43 October (4 Suppl.) (2008) S26-S40
20. Bracco N.H., Colucci A., Puccini R.F., and Farhat C.K. Immunogenicity of a combined DTPa-HB vaccine co-administered with Haemophilus influenzae type B conjugate vaccine (PRP-T) for primary and booster vaccinations. Braz J Infect Dis 9 October (5) (2005) 363-373
21. Bertoletti A., Sette A., Chisari F.V., Penna A., Levrero M., De Carli M., et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369 June (6479) (1994) 407-410
22. Berger R., Just M., and Gluck R. Interference between strains in live virus vaccines. I: combined vaccination with measles, mumps and rubella vaccine. J Biol Stand 16 October (4) (1988) 269-273
23. Berger R., and Just M. Interference between strains in live virus vaccines. II: combined vaccination with varicella and measles-mumps-rubella vaccine. J Biol Stand 16 October (4) (1988) 275-279
24. Dagan R., Eskola J., Leclerc C., and Leroy O. Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants. Infect Immun 66 May (5) (1998) 2093-2098
25. Frey S., Dagan R., Ashur Y., Chen X.Q., Ibarra J., Kollaritsch H., et al. Interference of antibody production to hepatitis B surface antigen in a combination hepatitis A/hepatitis B vaccine. J Infect Dis 180 December (6) (1999) 2018-2022
26. Fattom A., Cho Y.H., Chu C., Fuller S., Fries L., and Naso R. Epitopic overload at the site of injection may result in suppression of the immune response to combined capsular polysaccharide conjugate vaccines. Vaccine 17 January (2) (1999) 126-133
27. Larke N., Im E.J., Wagner R., Williamson C., Williamson A.L., McMichael A.J., et al. Combined single-clade candidate HIV-1 vaccines induce T cell responses limited by multiple forms of in vivo immune interference. Eur J Immunol 37 February (2) (2007) 566-577
28. Singh R.A., Rodgers J.R., and Barry M.A. The role of T cell antagonism and original antigenic sin in genetic immunization. J Immunol 169 December (12) (2002) 6779-6786
29. Guy B., Barban V., Mantel N., Aguirre M., Gulia S., Pontvianne J., et al. Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg 80 February (2) (2009) 302-311
30. Xu Y., Wang Q., Han Y., Song G., and Xu X. Type-specific and cross-reactive antibodies induced by human papillomavirus 31 L1/L2 virus-like particles. J Med Microbiol 56 July (Pt. 7) (2007) 907-913
31. Xu Y.F., Wang Q.Y., Zhang H.T., Han Y.H., Song G.X., and Xu X.M. Encapsidating artificial human papillomavirus-16 mE7 protein in human papillomavirus-6b L1/L2 virus like particles. Chin Med J (Engl) 120 March (6) (2007) 503-508
32. Wang M., Wang L.L., Chen L.F., Han Y.H., Zou Y.H., Si J.Y., et al. Expression of human papillomavirus type 6 L1 and L2 isolated in China and self assembly of virus-like particles by the products. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 35 January (1) (2003) 27-34
33. Shi W., Liu J., Huang Y., and Qiao L. Papillomavirus pseudovirus: a novel vaccine to induce mucosal and systemic cytotoxic T-lymphocyte responses. J Virol 75 November (21) (2001) 10139-10148
34. Buck C.B., Pastrana D.V., Lowy D.R., and Schiller J.T. Efficient intracellular assembly of papillomaviral vectors. J Virol 78 January (2) (2004) 751-757
35. Pastrana D.V., Buck C.B., Pang Y.Y., Thompson C.D., Castle P.E., FitzGerald P.C., et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 321 April (2) (2004) 205-216
36. Kondo K., Ishii Y., Ochi H., Matsumoto T., Yoshikawa H., and Kanda T. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region. Virology 358 February (2) (2007) 266-272
37. Beiss B.K., Heimer E., Felix A., Burk R.D., Ritter D.B., Mallon R.G., et al. Type-specific and cross-reactive epitopes in human papillomavirus type 16 capsid proteins. Virology 184 September (1) (1991) 460-464
38. Fleury M.J., Touze A., de S.S., Bosch F.X., Klaustermeiyer J., and Coursaget P. Detection of human papillomavirus type 31-neutralizing antibodies from naturally infected patients by an assay based on intracellular assembly of luciferase-expressing pseudovirions. Clin Vaccine Immunol 15 January (1) (2008) 172-175
39. Hines J.F., Ghim S.J., Christensen N.D., Kreider J.W., Barnes W.A., Schlegel R., et al. Role of conformational epitopes expressed by human papillomavirus major capsid proteins in the serologic detection of infection and prophylactic vaccination. Gynecol Oncol 55 October (1) (1994) 13-20
40. Rizk R.Z., Christensen N.D., Michael K.M., Muller M., Sehr P., Waterboer T., et al. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol 89 January (Pt. 1) (2008) 117-129
41. Ryding J., Dahlberg L., Wallen-Ohman M., and Dillner J. Deletion of a major neutralizing epitope of human papillomavirus type 16 virus-like particles. J Gen Virol 88 March (Pt. 3) (2007) 792-802
42. Christensen N.D., Kirnbauer R., Schiller J.T., Ghim S.J., Schlegel R., Jenson A.B., et al. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology 205 November (1) (1994) 329-335
43. Christensen N.D., Hopfl R., DiAngelo S.L., Cladel N.M., Patrick S.D., Welsh P.A., et al. Assembled baculovirus-expressed human papillomavirus type 11 L1 capsid protein virus-like particles are recognized by neutralizing monoclonal antibodies and induce high titres of neutralizing antibodies. J Gen Virol 75 September (Pt. 9) (1994) 2271-2276
44. Cason J., Kambo P.K., Best J.M., and McCance D.J. Detection of antibodies to a linear epitope on the major coat protein (L1) of human papillomavirus type-16 (HPV-16) in sera from patients with cervical intraepithelial neoplasia and children. Int J Cancer 50 February (3) (1992) 349-355
45. Sapp M., Kraus U., Volpers C., Snijders P.J., Walboomers J.M., and Streeck R.E. Analysis of type-restricted and cross-reactive epitopes on virus-like particles of human papillomavirus type 33 and in infected tissues using monoclonal antibodies to the major capsid protein. J Gen Virol 75 December (Pt. 12) (1994) 3375-3383
46. Hunt J.D., Jackson D.C., Brown L.E., Wood P.R., and Stewart D.J. Antigenic competition in a multivalent foot rot vaccine. Vaccine 12 April (5) (1994) 457-464
47. Garland S.M., Steben M., Hernandez-Avila M., Koutsky L.A., Wheeler C.M., Perez G., et al. Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines. Clin Vaccine Immunol 14 June (6) (2007) 792-795
48. Gasparic M., Rubio I., Thones N., Gissmann L., and Muller M. Prophylactic DNA immunization against multiple papillomavirus types. Vaccine 25 June (23) (2007) 4540-4553
49. Hayball J.D., Robinson B.W., and Lake R.A. CD4+ T cells cross-compete for MHC class II-restricted peptide antigen complexes on the surface of antigen presenting cells. Immunol Cell Biol 82 April (2) (2004) 103-111
50. Hunt J.D., Brown L.E., Wood P.R., Stewart D.J., and Jackson D.C. Manipulation of the helper T cell response to influence antigenic competition occurring with a multivalent vaccine. Immunol Cell Biol 74 February (1) (1996) 81-89
51. Hunt J.D., Jackson D.C., Wood P.R., Stewart D.J., and Brown L.E. Immunological parameters associated with antigenic competition in a multivalent footrot vaccine. Vaccine 13 December (17) (1995) 1649-1657
52. Nikoskelainen S., Verho S., Jarvinen S., Madetoja J., Wiklund T., and Lilius E.M. Multiple whole bacterial antigens in polyvalent vaccine may result in inhibition of specific responses in rainbow trout (Oncorhynchus mykiss). Fish Shellfish Immunol 22 March (3) (2007) 206-217
53. Rizvi N., Chaturvedi U.C., and Mathur A. Antigenic competition between dengue and Coxsackie viruses for presentation to B cells by macrophages. Int J Exp Pathol 71 December (6) (1990) 761-770
54. Sedegah M., Charoenvit Y., Minh L., Belmonte M., Majam V.F., Abot S., et al. Reduced immunogenicity of DNA vaccine plasmids in mixtures. Gene Ther 11 March (5) (2004) 448-456
55. Schwartzkoff C.L., Egerton J.R., Stewart D.J., Lehrbach P.R., Elleman T.C., and Hoyne P.A. The effects of antigenic competition on the efficacy of multivalent footrot vaccines. Aust Vet J 70 April (4) (1993) 123-126
56. Klenerman P., and Zinkernagel R.M. Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 394 July (6692) (1998) 482-485